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ABSTRACT
Glioblastoma recurrence after aggressive therapy typically occurs within six 
months, and patients inevitably succumb to their disease. Tumor recurrence is driven 
by a subpopulation of cancer stem cells in glioblastoma (glioblastoma stem-like cells, 
GSCs), which exhibit resistance to cytotoxic therapies, compared to their non-stem-cell 
counterparts. Here, we show that the Cox-2 and Wnt signaling pathways are aberrantly 
activated in GSCs and interact to maintain the cancer stem cell identity. Cox-2 stimulates 
GSC self-renewal and proliferation through prostaglandin E2 (PGE2), which in turn 
activates the Wnt signaling pathway. Wnt signaling underlies PGE2-induced GSC self-
renewal and independently directs GSC self-renewal and proliferation. Inhibition of 
PGE2 enhances the effect of temozolomide on GSCs, but affords only a modest survival 
advantage in a xenograft model in the setting of COX-independent Wnt activation. Our 
findings uncover an aberrant positive feedback interaction between the Cox-2/PGE2 
and Wnt pathways that mediates the stem-like state in glioblastoma.
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with	 glioblastoma	 remain	 dismal.	 Disease	 recurrence	
after	 surgery,	 radiation	 and	 chemotherapy,	 typically	
occurs	 within	 six	 months,	 and	 patients	 inevitably	
succumb	to	disease	progression	at	just	over	one	year	[1].	
Emerging	recognition	of	the	cellular	heterogeneity	within	
glioblastoma	 has	 focused	 attention	 on	 a	 subpopulation	
of	 cancer	 stem	 cells	 (CSCs)	 in	 glioblastoma,	 called	
brain	 tumor-initiating	 cells	 or	 glioblastoma	 stem-like	
cells	(GSCs)	[2],	that	are	thought	to	contribute	to	tumor	
recurrence	 following	 therapy.	 Compared	 to	 their	 non-
stem-cell	 counterparts	 (differentiated	 glioma	 cells,	
DGCs),	GSCs	 exhibit	 resistance	 to	 chemotherapy-	 and	
radiation-induced	 cell	 death	 [3–5],	 often	 through	 co-
option	of	signaling	pathways	relevant	to	normal	stem	cell	
physiology	[6–9].	Conceivably,	these	pathways	could	be	
therapeutic	 targets	 to	 disable	 CSC-mediated	 treatment	
resistance.
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to	 play	 an	 important	 role	 in	 several	 human	 cancers,	
including	glioblastoma.	 In	prostate	 and	 colon	 cancer,	
elevated	 Cox-2	 expression	 has	 been	 associated	 with	
increased	angiogenesis,	tumor	invasion	and	promotion	
of	tumor	cell	resistance	to	apoptosis	[10–13].	Elevated	
Cox-2	 levels	 have	 also	 been	 found	 to	 correlate	 with	
earlier	recurrence	and	shorter	survival	in	patients	with	
gliomas	[14].
In	 addition	 to	 its	 roles	 in	 angiogenesis,	 tumor	








In	 the	 hematopoietic	 stem	 cell	 niche,	 Cox-2	
regulates	 vertebrate	 HSC	 induction	 and	 engraftment	
directly	through	production	of	PGE2	[19],	and	indirectly	
through	stabilization	of	β-catenin	protein	and	activation	
of	 the	Wnt	 pathway	 [20].	 In	 the	 adult	 mouse	 brain,	
activation	of	the	canonical	Wnt	signaling	(Wnt/β-catenin	
pathway)	 is	 not	 seen	 under	 resting	 state	 conditions,	
but	 is	 expressed	 when	 progenitor	 cells	 are	 dividing	







been	 implicated	as	a	downstream	 target	of	 the	Cox-2	
pathway	[23].
Cancer	 stem	 cell	 systems	 have	 been	 described	
as	 hierarchies	 in	 which	 the	 normal	 mechanisms	 by	
which	 stem	 cells	 systems	 are	 maintained	 have	 been	
dysregulated	 to	 allow	 uninhibited	 cell	 expansion	 and	
growth	[24].	Here,	we	show	that	Cox-2	is	constitutively	
activated	 in	 human	 GSCs,	 but	 not	 in	 normal	 human	
neural	 stem	 cells	 (NSCs).	 Cox-2	 signaling	 and	
production	 of	 PGE2	 results	 in	 increased	 GSC	
proliferation	and	self-renewal	in	both	GSCs	and	NSCs	
in vitro,	 while	 inhibition	 of	 Cox-2	 in	 GSCs	 induces	
cell	 differentiation	 and	 loss	 of	 the	 cancer	 stem-like	
cell	phenotype.	PGE2	further	promotes	the	GSC	state	
through	 its	 activation	 of	 the	Wnt/β-catenin	 pathway,	
which	 mediates	 PGE2-induced	 GSC	 self-renewal	
through	 its	 canonical	 pathway.	 Our	 findings	 uncover	
an	 aberrant	 interaction	 between	 the	Cox-2/PGE2	 and	
Wnt	 pathways	 that	 mediates	 the	 stem-like	 state	 in	
glioblastoma.
RESULTS
Cox-2 is expressed in human glioblastoma
To	 examine	 Cox-2	 expression	 in	 human	 glioma,	
we	first	performed	immunohistochemistry	for	Cox-2	in	
low-	 and	 high-grade	 glioma	 surgical	 specimens.	These	
studies	showed	Cox-2	expression	in	gliomas	and	in	glioma	
cells	within	 infiltrated	brain	 (Figure	1A).	We	 found	no	
expression	of	Cox-2	within	the	normal	brain	hemisphere	
or	 within	 the	 neurogenic	 regions	 of	 the	 adult	 mouse	
subventricular	zone	or	subgranular	zone	(Supplementary	
Figure	1).	Examination	of	glioma	expression	data	from	




Cox-2 is enriched in GSCs and promotes GSC 
proliferation through PGE2
As	 Cox-2	 has	 been	 implicated	 as	 a	 mediator	 of	
the	cancer	stem	cell	phenotype	 in	mouse	glioblastoma,	
we	 sought	 to	 determine	 if	 it	 has	 an	 analogous	 role	 in	
the	 human	 disease.	 We	 generated	 low-passage	 RFP-
expressing	patient-derived	GSC	lines	that	express	neural	
stem	 cell	 markers	 (Figure	 2A),	 form	 self-renewing	
neurospheres	 (Figure	 2B),	 and	 give	 rise	 to	 infiltrative	
brain	 tumors	 following	 orthotopic	 transplantation	 in	
immunocompromised	mice	[25]	(Figure	2C).	Western	blot	
analysis	utilizing	GSCs	and	NSCs	in	culture	confirmed	









As	 has	 been	 found	 in	 glioma	 cell	 lines	 and	 a	
mouse	 glioblastoma	 model,	 we	 postulated	 that	 Cox-
2	 activation	 could	 have	 a	 pro-proliferative	 effect	 on	
human	 GSCs	 through	 production	 of	 PGE2.	 Inhibition	





In	 contrast,	 treatment	 with	 the	 synthetic	 PGE2	 analog,	
iloprost,	resulted	in	enhanced	proliferation	in	both	GSCs	
and	NSCs	(Figure	3D).	Finally,	inoculation	of	a	heterotopic	




Cox-2 regulates stem-ness in GSCs





the	 differentiation	markers,	 GFAP	 and	 β-tubulin	 (Figure	
4A).	Conversely,	treatment	of	GSCs	with	iloprost	resulted	
in	a	significant	increase	in	expression	of	the	GSC	marker	
Sox2,	 and	 an	 associated	 decrease	 in	 expression	 of	 the	
differentiation	markers,	GFAP	and	β-tubulin,	 in	multiple	




approximated	 by	 sphere	 formation	 [26]	 (Figure	 4D-4F),	
while	treatment	with	the	PGE2	analog,	iloprost,	promoted	
GSC	sphere	formation	(Figure	4G).	These	findings	suggest	
that	Cox-2	 signaling	 is	 necessary	 to	maintain	 the	 cancer	
stem-like	cell	phenotype	in	glioblastoma.














iloprost	 resulted	 in	 an	 increase	 in	 β-catenin	 activation,	
as	 demonstrated	 by	 accumulation	 of	 phosphorylated	
β-catenin	 (Figure	 5B)	 [29–31].	 Conversely,	 PGE2	
inhibition	 with	 indomethacin,	 celecoxib,	 or	 siRNA	
against	 COX-2,	 resulted	 in	 a	 significant	 decrease	 in	







AXIN2,	 LEF1,	 TCF7,	 and	 CCND1	 expression,	 while	
PGE2	inhibition	with	indomethacin,	celecoxib,	or	siRNA	





Figure 2: Cox-2 is enriched in GSCs and results in production of PGE2.	 (A)	 GSC	 lines	 were	 subjected	 to	









against	 COX-2,	 resulted	 in	 a	 significant	 decrease	 in	
AXIN2,	LEF1,	TCF7,	 and	CCND1	 expression	 (Figure	
5D).	Our	findings	indicate	the	Cox-2	promotes	activation	
of	the	Wnt	signaling	pathway	in	GSCs.















no	 apparent	 effect	 on	GSC	 survival,	 as	 determined	 by	
expression	of	caspase-3	(data	not	shown).	Interestingly,	











COX-2 inhibition enhances the effect of 
temozolomide in glioblastoma
CSCs	 have	 been	 postulated	 to	 drive	 tumor	
recurrence	 following	 disease	 treatment	 through	 their	
preferential	resistance	to	cytotoxic	injury	and	cell	death	




Temozolomide	 is	 used	 as	 a	 first-line	 chemotherapeutic	












as	 determined	 by	 absolute	 cell	 count	 and	 staining	 for	
phosphorylated	 histone	 H2AX	 (γH2AX),	 compared	 to	
GSCs	treated	with	temozolomide	alone	(Figure	7A	and	
7B).	 Conversely,	 concurrent	 COX-2	 inhibition	 with	
indomethacin,	 celecoxib,	 or	 siRNA	 against	 COX-2,	
increased	the	cytotoxic	effect	of	temozolomide	on	GSCs,	





was	 limited	 and	non-sustained.	 Interestingly,	we	 found	
evidence	of	sustained	nuclear	β-catenin	staining	within	
surviving	 glioma	 cells	 in	 xenograft-harboring	 mice	
treated	with	temozolomide	and	indomethacin	compared	
to	xenograft-harboring	mice	treated	with	temozolomide	















cells	 located	 within	 the	 brain	 microenvironment,	 and	
suggest	 a	 mechanism	 underlying	 the	 limited	 survival	
benefit	conferred	by	concomitant	COX	inhibition	therapy.
DISCUSSION
In	 this	 study,	 we	 identify	 a	 cooperative	 role	 for	
Cox-2	 and	 Wnt/β-catenin	 as	 mediators	 of	 the	 CSC	
phenotype	 in	glioblastoma.	Cox-2	 is	enriched	 in	GSCs	
and	promotes	GSC	proliferation	and	self-renewal	through	




in	 increased	 levels	 of	 β-catenin	 and	 phosphorylated	
β-catenin.	Finally,	inhibition	of	the	Wnt	pathway	abrogates	




been	 studied	 intensively	 as	 oncogenic	 drivers	 and	 are	







shown	an	 inverse	 correlation	between	 the	 incidence	of	
colon	cancer	and	the	use	of	nonsteroidal	anti-inflammatory	
drugs	 (NSAIDs),	which	 inhibit	 prostaglandin	 synthesis	
[43–45].	Similarly,	WNT1	overexpression	induced	by	a	
proviral	insertion	at	the	Wnt1	locus	induces	spontaneous	
mammary	 hyperplasia	 and	 tumours	 in	 mice	 [46,	 47],	
and	Wnt1	 transgenic	mice	 similarly	develop	mammary	
tumours,	suggesting	a	causative	role	for	WNT1	in	breast	









β-catenin	 degradation	 through	 a	 cAMP/PKA-mediated	




















pathway,	 which	 in	 turn	 stimulates	 GSC	 proliferation	
and	self-renewal.	Interestingly,	Wnt	inhibition	abrogates	
Figure 6: Wnt pathway activation mediates self-renewal in GSCs.	(A, B)	Wnt	activation	in	GSCs	through	treatment	with	the	
GSK3b-inhibitor	lithium	chloride	(10	mM)	promotes	GliNS1	GSC	proliferation	and	self-renewal,	as	determined	by	BrdU	incorporation	










found	 to	direct	 symmetric	 cell	division	 in	 adult	mouse	
NSCs	[21],	and	has	been	found	to	be	a	critical	target	of	
PGE2	during	HSC	 specification	 and	 regeneration	 [20].	










The	 Wnt	 signaling	 pathway	 has	 recently	 been	
described	 to	 be	 constitutively	 activated	 in	 a	 subgroup	
of	glioblastomas,	 and	 it	 is	 possible	 that	 the	kinetics	of	







processes	 in	 glioblastoma,	 and	 prompt	 further	 study	




was	 performed	 at	 the	 University	 of	 Toronto,	 Toronto,	
Ontario,	and	Washington	University,	St.	Louis,	Missouri.	
All	 experiments	 were	 performed	 in	 accordance	 with	
the	 relevant	 guidelines	 and	 regulations	 of	 these	 two	
institutions.
Immunohistochemistry in human glioblastoma 
specimens
Human	glioblastoma	 specimens	 and	 clinical	 data	
were	obtained	from	the	St.	Michael	Hospital	Brain	Tumour	
Biobank	and	Brain	Tumour	Research	Centre,	Hospital	for	
Sick	 Children,	 following	 approval	 by	 the	 Institutional	
Research	Ethics	Boards	of	both	institutions.	All	samples	
were	de-identified	before	analysis.	Tissue	samples	were	













cooking	 in	 10uM	 citrate	 buffer	 at	 pH6.0,	 secondary	
HRP	anti-Rabbit	 IgG	(Vector	 lab	1:250),	and	detection	




with	 a	 Quorum	 Spinning	 Disk	 Confocal	 Microscope	
(Olympus)	running	Volocity	software	(Perkin	Elmer).
Analysis of COX2 expression in glioblastoma 
from TCGA
TCGA	 GBM	 RNAseq	 data	 was	 accessed	 using	







was	 obtained	 from	 patients	 for	 use	 of	 human	 tissue	
and	cells,	and	all	human	tissue-related	protocols	used	
in	 this	 study	 were	 approved	 by	 the	 Review	 Ethics	
Board	(University	of	Toronto).	In	brief,	tumor	samples	












Technologies).	All	 cell	 lines	 were	 incubated	 at	 37°C	
with	5%	CO2.














animal	 protocols	 and	 approved	 by	 the	Animal	 Studies	
Committee	of	the	University	of	Toronto.	For	heterotopic	
(flank)	model	studies,	50,000	cells	were	injected	in	the	
mouse	 flank	 of	 approximately	 6-week-old	NOD-SCID	
mice.	Drug	administration	in	the	flank	xenograft	model	
was	 performed	 through	 direct	 intratumoral	 injection	
using	a	volume	of	200	uL	per	injection	of	either	normal	












supernatants	 were	 quantified	 using	 the	 BCA	 protein	
assay.	 Fifteen	 micrograms	 of	 protein	 were	 separated	
on	 10%	 acrylamide/bisacrylamide	 gels	 and	 transferred	
to	 PVDF	 membranes.	 PVDF	 membranes	 and	 blocked	
with	5%	(w/v)	skim	milk	in	PBS/0.1%	Tween-20	for	1	
h	 at	 room	 temperature.	 Membranes	 were	 shaken	 with	




primary	 antibodies	were	 used:	 β-actin	 (Cell	 Signaling,	
1:10,000),	 Cox-2	 (Abcam,	 1:1000),	 β-catenin	 (Cell	
Signaling	 Technology,	 1:1000),	 phospho-β-catenin	
Ser675	(Cell	Signaling	Technology,	1:1000),	and	cleaved	
caspase	3	(Cell	Signaling	Technology,	1:1000).	Protein	
quantification	 was	 performed	 by	 densitometry	 (Image	
Studio,	 LI-COR).	 Protein	 levels	 were	 normalized	 for	
β-actin.
ELISA assay




Total	 RNA	 was	 extracted	 from	 cells	 in	 culture	
using	an	RNAEasy	Kit	according	to	the	manufacturer’s	




Biosystems)	 with	 a	 StepOne	 Real	 Time	 PCR	 System.	
Predesigned	 primers	 were	 purchased	 from	 IDT.	 Gene	
transcript	levels	were	calculated	using	the	ΔΔCt	method.
Short interfering RNA knockdown
Predesigned	 short	 interfering	 (si)RNAs	 targeting	







TCGA	 level	 3	 data	 was	 gathered	 using	 TCGA-
Assembler	 retrieving	 RNA-seqV2	 data	 and	 clinical	
data	 for	 glioblastoma	 and	 low-grade	 glioma	 as	 above.	
RSEM	normalized	expression	values	were	used	to	group	
glioblastomas	 by	 COX2	 expression.	 Glioblastomas	
expressing	COX2	 in	 the	first	quartile	were	assigned	as	
COX2-high	expressing	and	GBMs	with	COX2	expression	
in	 the	4th	 quartile	was	 assigned	COX2-low	expressing.	
Boxplots	 of	 TCF/LEF	 target	 genes	 were	 performed	




RNA-seq	 fastq	 data	 was	 obtained	 via	 accession	
no.	 GSE57872.	 Paired-end	 25	 bp	 reads	 were	 mapped	
to	UCSC	human	genome	(hg38)	by	STAR	(version	2.5	
using	default	parameters).	Differential	expression	of	genes	
was	 performed	 using	 DESeq2	 [58].	 Log2	 transformed	
count	 matrix	 for	 TCF/LEF	 target	 genes	 with	 adjusted	
p-value	<	0.05	were	plotted	in	a	heatmap	with	R	package	
“pheatmap”.
Xenograft tissue preparation and 
immunohistochemistry
Adult	mice	 (Jackson	 labs)	were	 anesthetised	with	
Avertin	 (2,	 2,	 2-tribromoethanol,	 Sigma)	 and	 perfused	
with	 4%	 paraformaldehyde.	 Brains	 were	 post-fixed	
overnight	and	cryoprotected	in	20%	sucrose	at	4°C	until	






incubated	with	 rabbit	 β-catenin	 (abcam,	 1:100)	 primary	
antibody	overnight	at	4°C.	The	following	day,	slides	were	
washed	 with	 PBS	 and	 incubated	 with	Alexa	 Fluor	 488	







signal	 within	 RFP-positive	 cells	 was	 performed	 using	
ImageJ	(https://imagej.nih.gov/ij/).
Statistics
All	 images	 are	 representative	 of	 results	 from	
three	independent	experiments	unless	otherwise	stated.	
Statistical	 analyses	 were	 performed	 with	 Prism	 7.0b	
(GraphPad),	 Excel	 (Microsoft),	 or	 R	 Version	 3.1.1	
software.	 The	 unpaired	 Student’s	 t-test	 was	 used	 for	
comparisons	 in	 experiments	 with	 only	 two	 groups.	
In	 experiments	 with	 more	 than	 two	 comparison	
groups,	ANOVA	was	performed.	Record	of	 statistical	
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